/AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial)

Citation Map

Citing

Cited By

The articles shown here are a subset.See the full list of articles below.

Citing (0)

Sort By:

Data not found

Cited By (0)

Sort By: